Sequenom News

Mr. Zaniboni previously served as Chief Financial Officer of healthcare software solutions company Awarepoint and XIFIN Inc., a provider of revenue cycle management for diagnostic service providers.

Main Category: Pregnancy / Obstetrics Also Included In: Pediatrics / Children's Health ; Genetics Article Date: 07 Feb 2012 - 0:00 PST A newly available DNA-based prenatal blood test that can identify a pregnancy with Down syndrome can also identify two additional chromosome abnormalities: trisomy 18 and trisomy 13 .The test for all three defects ... (more)

Sequenom was upgraded by Zacks Investment Research from a "neutral" rating to an "outperform" rating in a research note issued to investors on Monday.

A newly available DNA-based prenatal blood test that can identify a pregnancy with Down syndrome can also identify two additional chromosome abnormalities: trisomy 18 and trisomy 13 .

A newly available DNA-based prenatal blood test that can identify a pregnancy with Down syndrome can also identify two additional chromosome abnormalities: trisomy 18 and trisomy 13 .

Separately, analysts at Dougherty & Co initiated coverage on shares of Sequenom in a research note to investors on Thursday, January 5th.

Sequenom, Inc. today announced the completion of an underwritten public offering of 14,950,000 shares of its common stock, including 1,950,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters.

Sequenom, Inc. today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.

Diagnostic test maker Sequenom Inc . said Friday it will sell 13 million shares of its stock for $4.15 each.

SAN DIEGO &#8212 Diagnostic test maker Sequenom Inc. said Friday it will sell 13 million shares of its stock for $4.15 each.